Thursday, April 28, 2016

AbbVie to buy Stemcentrx in $5.8 bln deal

April 28 (Reuters) - Drugmaker AbbVie Inc said it

would buy privately held oncology company Stemcentrx in a deal

valued at $5.8 billion in cash and stock.

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)